T细胞在天疱疮发病机制中的研究进展

doi:10.35541/cjd.20240023

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (10): 955-959.doi: 10.35541/cjd.20240023

T细胞在天疱疮发病机制中的研究进展

唐冬梅闫雨柔许银德李晓岚

昆明医科大学第二附属医院皮肤性病科，昆明 650101

收稿日期:2024-01-15 修回日期:2024-05-15 发布日期:2024-09-29
通讯作者: 李晓岚 E-mail:prolixl@163.com

Role of T cells in the pathogenesis of pemphigus

Tang Dongmei, Yan Yurou, Xu Yinde, Li Xiaolan

Department of Dermatology and Venereology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

Received:2024-01-15 Revised:2024-05-15 Published:2024-09-29
Contact: Li Xiaolan E-mail:prolixl@163.com

摘要/Abstract

摘要： 【摘要】天疱疮是一组危及生命的慢性自身免疫性疱病。目前认为抗桥粒芯糖蛋白IgG抗体介导的体液免疫是天疱疮发病的主要机制，而最近的研究显示，T细胞各亚类在天疱疮的发病中也起到关键作用。

关键词: 天疱疮, 桥粒芯糖蛋白质类, CD4阳性T淋巴细胞, CD8阳性T淋巴细胞, T淋巴细胞, 调节性, T淋巴细胞, 辅助诱导

Abstract: 【Abstract】 Pemphigus is a group of life-threatening chronic autoimmune blistering diseases. It is currently believed that the humoral immunity mediated by anti-desmoglein IgG antibodies is the primary mechanism underlying the pathogenesis of pemphigus. However, recent studies have indicated a critical role of various T cell subsets in the onset of pemphigus.

Key words: Pemphigus, Desmogleins, CD4-positive T-lymphocytes, CD8-positive T-lymphocytes, T-lymphocytes, regulatory, T-lymphocytes, helper-inducer

唐冬梅闫雨柔许银德李晓岚. T细胞在天疱疮发病机制中的研究进展[J]. 中华皮肤科杂志, 2024,57(10):955-959. doi:10.35541/cjd.20240023

Tang Dongmei, Yan Yurou, Xu Yinde, Li Xiaolan. Role of T cells in the pathogenesis of pemphigus[J]. Chinese Journal of Dermatology, 2024, 57(10): 955-959.doi:10.35541/cjd.20240023

参考文献 48

［1］	Araghi F, Dadkhahfar S, Robati RM, et al. The emerging role of T cells in pemphigus vulgaris: a systematic review［J］. Clin Exp Med, 2023,23（4）:1045⁃1054. doi: 10.1007/s10238⁃022⁃00855⁃8.
［2］	Yuan Q, Yang W, Zhang X. Immune cells in pemphigus vulgaris and bullous pemphigoid: from pathogenic roles to targeting therapies［J］. Int Immunopharmacol, 2023,123:110694. doi: 10. 1016/j.intimp.2023.110694.
［3］	Takahashi H, Iriki H, Asahina Y. T cell autoimmunity and immune regulation to desmoglein 3, a pemphigus autoantigen［J］. J Dermatol, 2023,50（2）:112⁃123. doi: 10.1111/1346⁃8138.16663.
［4］	Khantakova JN, Sennikov SV. T⁃helper cells flexibility: the possibility of reprogramming T cells fate［J］. Front Immunol, 2023,14:1284178. doi: 10.3389/fimmu.2023.1284178.
［5］	Butcher MJ, Zhu J. Recent advances in understanding the Th1/Th2 effector choice［J］. Fac Rev, 2021,10:30. doi: 10.12703/r/10⁃30.
［6］	Hertweck A, Vila de Mucha M, Barber PR, et al. The TH1 cell lineage⁃determining transcription factor T⁃bet suppresses TH2 gene expression by redistributing GATA3 away from TH2 genes［J］. Nucleic Acids Res, 2022,50（8）:4557⁃4573. doi: 10.1093/nar/gkac258.
［7］	Liu Q, Cui F, Wang M, et al. Increased expression of microRNA⁃338⁃3p contributes to production of Dsg3 antibody in pemphigus vulgaris patients［J］. Mol Med Rep, 2018,18（1）:550⁃556. doi: 10.3892/mmr.2018.8934.
［8］	Chen J, Zhang Y, Liang Y, et al. Regulatory effects of Nr4a2 on Th2 cells from patients with pemphigus vulgaris［J］. Oncotarget, 2018,9（13）:11258⁃11267. doi: 10.18632/oncotarget.24371.
［9］	田晶, 梁源, 申春平, 等. 儿童中重度特应性皮炎首次皮下注射度普利尤单抗短期疗效和安全性分析［J］. 中华皮肤科杂志, 2022,55（4）:299⁃303. doi: 10.35541/cjd.20210734.
［10］	Jiang C, Adjei S, Santiago S, et al. Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus［J］. JAAD Case Rep, 2023,42:12⁃15. doi: 10.1016/j.jdcr.2023.09.018.
［11］	Moore AY, Hurley K. Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris［J］. JAAD Case Rep, 2023,31:16⁃18. doi: 10.1016/j.jdcr.2022.10.035.
［12］	Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases［J］. Semin Immunopathol, 2019,41（3）:283⁃297. doi: 10.1007/s00281⁃019⁃00733⁃8.
［13］	Schinner J, Cunha T, Mayer JU, et al. Skin⁃infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris［J］. Front Immunol, 2023,14:1203776. doi: 10.3389/fimmu.2023.1203776.
［14］	Ansari MA, Singh PK, Dar SA, et al. Deregulated phenotype of autoreactive Th17 and Treg clone cells in pemphigus vulgaris after in⁃vitro treatment with desmoglein antigen （Dsg⁃3）［J］. Immunobiology, 2023,228（2）:152340. doi: 10.1016/j.imbio.2023. 152340.
［15］	Holstein J, Solimani F, Baum C, et al. Immunophenotyping in pemphigus reveals a T（H）17/T（FH）17 cell⁃dominated immune response promoting desmoglein1/3⁃specific autoantibody production［J］. J Allergy Clin Immunol, 2021,147（6）:2358⁃2369. doi: 10. 1016/j.jaci.2020.11.008.
［16］	Xu C, Zhang T, Wang H, et al. Integrative single⁃cell analysis reveals distinct adaptive immune signatures in the cutaneous lesions of pemphigus［J］. J Autoimmun, 2024,142:103128. doi: 10.1016/j.jaut.2023.103128.
［17］	Chen Y, Wang YF, Song SS, et al. Potential shared therapeutic and hepatotoxic mechanisms of Tripterygium wilfordii polyglycosides treating three kinds of autoimmune skin diseases by regulating IL⁃17 signaling pathway and Th17 cell differentiation［J］. J Ethnopharmacol, 2022,296:115496. doi: 10.1016/j.jep.2022.115496.
［18］	Tada Y, Morita A, Yamanaka K, et al. Real⁃world retention rates and effectiveness of secukinumab in psoriasis: results from a multicenter cohort study （RAILWAY）［J］. J Dermatol, 2023,50（11）:1415⁃1426. doi: 10.1111/1346⁃8138.16926.
［19］	Kohlmann J, Simon JC, Kunz M, et al. Possible effect of interleukin⁃17 blockade in pemphigus foliaceus and neutrophilic diseases［J］. Hautarzt, 2019,70（8）:641⁃644. doi: 10.1007/s00105⁃019⁃4414⁃8.
［20］	Lin X, Chen M, Li X, et al. Low SOCS3 expression in CD4（+） T cells from pemphigus vulgaris patients enhanced Th1⁃ and Th17⁃cell differentiation and exacerbated acantholysis via STAT activation［J］. Mol Immunol, 2022,150:114⁃125. doi: 10.1016/j.molimm.2022.08.007.
［21］	Singh PK, Das S, Rai G, et al. A snapshot of T cell subset cytokines in pemphigus vulgaris: a cross⁃sectional study［J］. Cureus, 2022,14（10）:e29890. doi: 10.7759/cureus.29890.
［22］	Attias M, Al⁃Aubodah T, Piccirillo CA. Mechanisms of human FoxP3（+） T（reg） cell development and function in health and disease［J］. Clin Exp Immunol, 2019,197（1）:36⁃51. doi: 10. 1111/cei.13290.
［23］	Abd El⁃Magid WM, Ahmed SF, Assaf H, et al. Immunohistochemical expression of regulatory T cells （CD（4）（+） CD（25）（+） bright FOXP（3）（+）） in pemphigus patients［J］. J Cosmet Dermatol, 2022,21（10）:4871⁃4876. doi: 10.1111/jocd.14854.
［24］	Iriki H, Takahashi H, Amagai M. Diverse role of OX40 on T cells as a therapeutic target for skin diseases［J］. J Invest Dermatol, 2023,143（4）:545⁃553. doi: 10.1016/j.jid.2022.11.009.
［25］	Xu M, Liu Q, Li S, et al. Increased expression of miR⁃338⁃3p impairs Treg⁃mediated immunosuppression in pemphigus vulgaris by targeting RUNX1［J］. Exp Dermatol, 2020,29（7）:623⁃629. doi: 10.1111/exd.14111.
［26］	Lai K, Zhang W, Li S, et al. mTOR pathway regulates the differentiation of peripheral blood Th2/Treg cell subsets in patients with pemphigus vulgaris［J］. Acta Biochim Biophys Sin （Shanghai）, 2021,53（4）:438⁃445. doi: 10.1093/abbs/gmab008.
［27］	Qi J, Liu C, Bai Z, et al. T follicular helper cells and T follicular regulatory cells in autoimmune diseases［J］. Front Immunol, 2023,14:1178792. doi: 10.3389/fimmu.2023.1178792.
［28］	Mesas⁃Fernández A, Bodner E, Hilke FJ, et al. Interleukin⁃21 in autoimmune and inflammatory skin diseases［J］. Eur J Immunol, 2023,53（4）:e2250075. doi: 10.1002/eji.202250075.
［29］	Wei X, Niu X. T follicular helper cells in autoimmune diseases［J］. J Autoimmun, 2023,134:102976. doi: 10.1016/j.jaut.2022. 102976.
［30］	Hennerici T, Pollmann R, Schmidt T, et al. Increased frequency of T follicular helper cells and elevated interleukin⁃27 plasma levels in patients with pemphigus［J/OL］. PLoS One, 2016,11（2）:e0148919. doi: 10.1371/journal.pone.0148919.
［31］	Maho⁃Vaillant M, Perals C, Golinski ML, et al. Rituximab and corticosteroid effect on desmoglein⁃specific B cells and desmoglein⁃specific T follicular helper cells in pemphigus［J］. J Invest Dermatol, 2021,141（9）:2132⁃2140.e1. doi: 10.1016/j.jid.2021.01.031.
［32］	Wang C, Zhang H, Liu T, et al. Circulating Tfr/Tfh cell imbalance may contribute to the immunopathogenesis of pemphigus［J］. J Eur Acad Dermatol Venereol, 2023,37（12）:e1399⁃e1402. doi: 10.1111/jdv.19338.
［33］	Kim AR, Han D, Choi JY, et al. Targeting inducible costimulator expressed on CXCR5（+）PD⁃1（+） T（H） cells suppresses the progression of pemphigus vulgaris［J］. J Allergy Clin Immunol, 2020,146（5）:1070⁃1079.e8. doi: 10.1016/j.jaci.2020.03.036.
［34］	Sun L, Su Y, Jiao A, et al. T cells in health and disease［J］. Signal Transduct Target Ther, 2023,8（1）:235. doi: 10.1038/s41392⁃023⁃01471⁃y.
［35］	Moon JS, Younis S, Ramadoss NS, et al. Cytotoxic CD8（+） T cells target citrullinated antigens in rheumatoid arthritis［J］. Nat Commun, 2023,14（1）:319. doi: 10.1038/s41467⁃022⁃35264⁃8.
［36］	Li H, Tsokos GC. Double⁃negative T cells in autoimmune diseases［J］. Curr Opin Rheumatol, 2021,33（2）:163⁃172. doi: 10.1097/BOR.0000000000000778.
［37］	Murayama K, Ikegami I, Kamekura R, et al. CD4（+）CD8（+） T follicular helper cells regulate humoral immunity in chronic inflammatory lesions［J］. Front Immunol, 2022,13:941385. doi: 10.3389/fimmu.2022.941385.
［38］	Bhanusali DG, Sachdev A, Rahmanian A, et al. HLA⁃E*0103X is associated with susceptibility to pemphigus vulgaris［J］. Exp Dermatol, 2013,22（2）:108⁃112. doi: 10.1111/exd.12077.
［39］	El⁃Naby SE⁃SA, Amin M, Ali MH, et al. Evaluation of the relation between T⁃lymphocytes （CD4 ve and CD8 ve） and pemphigus vulgaris pathogenesis and severity［J］. Indian J Dermatopathol Diagn Dermatol, 2019,6（1）:30⁃35. doi: 10.4103/ijdpdd.ijdpdd_70_18.
［40］	Giurdanella F, Fania L, Gnarra M, et al. A possible role for CD8+ T lymphocytes in the cell⁃mediated pathogenesis of pemphigus vulgaris［J］. Mediators Inflamm, 2013,2013:764290. doi: 10.1155/2013/764290.
［41］	Muro R, Takayanagi H, Nitta T. T cell receptor signaling for γδT cell development［J］. Inflamm Regen, 2019,39:6. doi: 10.1186/s41232⁃019⁃0095⁃z.
［42］	Das D, Anand V, Khandpur S, et al. T helper type 1 polarizing γδ T cells and scavenger receptors contribute to the pathogenesis of pemphigus vulgaris［J］. Immunology, 2018,153（1）:97⁃104. doi: 10.1111/imm.12814.
［43］	Das D, Arava S, Khandpur S, et al. Dominance and improved survivability of human γδT17 cell subset aggravates the immunopathogenesis of pemphigus vulgaris［J］. Immunol Res, 2024,72（1）:72⁃81. doi: 10.1007/s12026⁃023⁃09413⁃0.
［44］	Fazeli P, Kalani M, Hosseini M. T memory stem cell characteristics in autoimmune diseases and their promising therapeutic values［J］. Front Immunol, 2023,14:1204231. doi: 10.3389/fimmu.2023.1204231.
［45］	Emmanuel T, Mistegård J, Bregnhøj A, et al. Tissue⁃resident memory T cells in skin diseases: a systematic review［J］. Int J Mol Sci, 2021,22（16）:9004. doi: 10.3390/ijms22169004.
［46］	Karagaiah P, Schwartz RA, Lotti T, et al. Biologic and targeted therapeutics in vitiligo［J］. J Cosmet Dermatol, 2023,22（1）:64⁃73. doi: 10.1111/jocd.14770.
［47］	Richmond JM, Strassner JP, Rashighi M, et al. Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo［J］. J Invest Dermatol, 2019,139（4）:769⁃778. doi: 10.1016/j.jid.2018.10.032.
［48］	Zou Y, Yuan H, Zhou S, et al. The Pathogenic role of CD4+ tissue⁃resident memory T cells bearing T follicular helper⁃like phenotype in pemphigus lesions［J］. J Invest Dermatol, 2021,141（9）:2141⁃2150. doi: 10.1016/j.jid.2021.01.030.

[1]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746.
[2]	任伟琦邹雅茹潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772.
[3]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[4]	马铜川邓婷月肖风丽. 吸烟与特应性皮炎相关性研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220793-e20220793.
[5]	郭蕾曹春艳方晓雅冯素英. 自身免疫性大疱病患者创面感染多重耐药菌现况及危险因素分析[J]. 中华皮肤科杂志, 2024, 57(2): 155-160.
[6]	潘萌王麒钧. 寻常型天疱疮的治疗难点与对策[J]. 中华皮肤科杂志, 2024, 57(10): 891-894.
[7]	王刚. 大疱性类天疱疮的治疗难点与对策[J]. 中华皮肤科杂志, 2024, 57(10): 887-890.
[8]	陈妍陈丹阳陈喜雪尚盼盼王明悦. 度普利尤单抗在104例大疱性类天疱疮患者中的应用及疗效影响因素分析[J]. 中华皮肤科杂志, 2024, 57(10): 925-930.
[9]	胡珺鈺陈丹阳陈喜雪王明悦. 度普利尤单抗联合米诺环素或联合米诺环素及系统糖皮质激素治疗大疱性类天疱疮的队列研究[J]. 中华皮肤科杂志, 2024, 57(10): 917-924.
[10]	李锁荆可王媛李志量赵晨静张寒梅梁桂熔冯素英. 抗p200类天疱疮35例临床及免疫血清学特征回顾性分析[J]. 中华皮肤科杂志, 2024, 57(10): 897-903.
[11]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. [开放获取] 中国天疱疮诊疗指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(10): 873-886.
[12]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[13]	闪莹常晓彤左亚刚. 自身免疫性疱病的表位扩展现象[J]. 中华皮肤科杂志, 2023, 56(7): 702-705.
[14]	焦晓燕尹光文李冬芹阴亚坤蔡丙杰方慧. 伴脑卒中的大疱性类天疱疮74例临床分析[J]. 中华皮肤科杂志, 2023, 56(4): 330-334.
[15]	中国医师协会皮肤科医师分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心 . [开放获取] 天疱疮患者健康教育共识（2023版）[J]. 中华皮肤科杂志, 2023, 0(4): 20230123-e20230123.

T细胞在天疱疮发病机制中的研究进展

Role of T cells in the pathogenesis of pemphigus

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

Metrics

本文评价

推荐阅读 10